RB1 and pure red-cell aplasia: Accumulating genomic evidence revealed a homozygous RB1 deletion in ∼5–10% of primary PRCA, which increased to ∼60% in metastatic and androgen receptor inhibitor‐resistant/castration‐resistant PRCA (CRPC), along with increased neuroendocrine features [7, 8].